Next, we evaluated the efficacy of RETi selpercatinib and CDK4/6i palbociclib, alone or combined, in ER+ patient-derived breast cancer organoids (PDO-P48) that exhibited high IC50 towards CDK4/6i, and thus primary resistance to this treatment (Figure 5). This evidence concerns the gene CDK4 and breast carcinoma.